MetLife Investment Management’s Achillion Pharmaceuticals ACHN Stock Holding History

MetLife Investment Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-51,647	Closed	-$311K	–	2360
2019 Q4	$311K	Sell	51,647 -15,915	-24%	-$92.1K	﹤0.01%	1724
2019 Q3	$243K	Hold	67,562	–	–	﹤0.01%	1835
2019 Q2	$181K	Hold	67,562	–	–	﹤0.01%	2087
2019 Q1	$200K	Buy	+67,562	New	+$166K	﹤0.01%	1985
2018 Q4	–	Sell	-65,605	Closed	-$241K	–	2622
2018 Q3	$241K	Buy	65,605 +9,502	+17%	+$28.3K	﹤0.01%	1974
2018 Q2	$159K	Hold	56,103	–	–	﹤0.01%	2023
2018 Q1	$208K	Hold	56,103	–	–	﹤0.01%	1870
2017 Q4	$162K	Buy	+56,103	New	+$204K	﹤0.01%	2034

MetLife Investment Management's ACHN Position: Q1 2020 in Review

MetLife Investment Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 51,647 shares — an estimated $311K sold.

MetLife Investment Management first reported a position in ACHN in Q4 2017 and held it in 8 quarters. The position peaked at $311K in Q4 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.

MetLife Investment Management reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
MetLife Investment Management sold 51,647 Achillion Pharmaceuticals shares in Q1 2020, an estimated $311K.
MetLife Investment Management first reported a position in Achillion Pharmaceuticals in Q4 2017 and held it in 8 quarters.
MetLife Investment Management's Achillion Pharmaceuticals position peaked at $311K in Q4 2019.
0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.

Based on MetLife Investment Management's 13F filing for Q1 2020, filed 15 May 2020.